LYMPHOMA, NON-HODGKIN

This study is testing an experimental treatment called JCAR017, a type of CAR-T cell therapy, in adults whose slow-growing non-Hodgkin lymphoma has come back or hasn't responded to prior treatments. Doctors will collect a patient's own immune cells, genetically modify them to bet…

This early-stage study is testing the safety and initial effectiveness of a new oral drug called LOXO-338 for patients with advanced blood cancers like leukemia and lymphoma who have already received standard therapies. The trial has two parts: first testing LOXO-338 alone, and t…

This study aims to find the best COVID-19 booster strategy for people with weakened immune systems, such as those with HIV, organ transplants, or certain cancers. It will compare giving one versus two extra doses of approved mRNA vaccines to see which is safer and builds stronger…

This study is testing a new oral drug called CC-99282 for people with non-Hodgkin lymphoma that has come back or hasn't responded to previous treatments. Researchers want to find the safest and most effective dose, both when given alone and when combined with other lymphoma drugs…

This study provides continued access to the cancer drug ibrutinib for patients who benefited from it in previous clinical trials but cannot obtain it through regular commercial channels. It allows about 300 patients with various blood cancers or solid tumors to keep receiving the…

This is the first human study of an experimental drug called JNJ-87801493, given alongside other drugs that help the immune system fight cancer. The main goal is to find a safe dose and understand the side effects in 70 adults with B-cell non-Hodgkin lymphoma that has returned or…

This study is testing a new cell therapy for people whose Hodgkin's or Non-Hodgkin's lymphoma has come back or hasn't responded to standard treatments. Doctors take a patient's own immune cells, modify them in a lab to better target cancer cells, and then infuse them back into th…

This study is testing a new, personalized way to calculate the dose of melphalan chemotherapy given to lymphoma patients before a stem cell transplant. Instead of using a standard dose based on height and weight, researchers are using a mathematical model to calculate an optimal …

This study is testing a two-step stem cell transplant for adults with high-risk non-Hodgkin's lymphoma. First, patients receive a transplant using their own cells, followed by a second, gentler transplant using cells from a matched donor. The goal is to see if this combined appro…

This study is testing a specific type of stem cell transplant for patients with various blood cancers. It uses stem cells from a partially matched family donor instead of bone marrow. The main goals are to see how well patients survive and recover, and to learn how the immune sys…

This study is testing a new cell therapy for lymphoma that has come back after treatment and is linked to Epstein-Barr virus (EBV). Researchers are giving patients special immune cells (T cells) that have been genetically modified to resist a substance released by the tumor and t…

This is the first study in people testing a new oral medication called JNJ-88998377 for patients with B-cell non-Hodgkin's lymphoma that has returned or not responded to other treatments. The main goals are to check the drug's safety and figure out the best dose for future testin…

This is the first human study of an experimental drug called JNJ-80948543, designed to redirect a patient's own immune T-cells to attack cancer cells. It is enrolling 167 adults with advanced non-Hodgkin lymphoma or chronic lymphocytic leukemia that has come back or stopped respo…

This early-stage study is testing the safety of a new two-drug combination for people with aggressive B-cell lymphoma that has come back or stopped responding to standard treatments. The main goal is to find a safe and tolerable dose for future testing. Researchers will also chec…

This study is testing a new drug called englumafusp alfa, given with other approved lymphoma drugs, for people whose Non-Hodgkin's lymphoma has come back or hasn't responded to previous treatments. The main goals are to find a safe dose and see if the combination can shrink tumor…

This study is testing a new electronic program that combines mindfulness and music therapy. It aims to help patients feel better and manage symptoms during and after a difficult stem cell transplant for blood cancers. The research will see if this program improves quality of life…

This study is testing whether a drug called siltuximab can help control two serious side effects that sometimes occur after CAR-T cell therapy for blood cancers. CAR-T therapy can cause dangerous immune overreactions called cytokine release syndrome (CRS) and neurological problem…

This study aims to understand the genetic causes of cancer that run in families. Researchers are collecting blood or saliva samples from patients with certain cancers and their relatives to build a DNA bank. The goal is to identify genetic patterns that increase cancer risk, whic…

This study aims to build a large, diverse group of 21,000 people newly diagnosed with non-Hodgkin lymphoma to learn what affects their long-term health. It will collect detailed health information, lifestyle factors, and biological samples over time, but does not test a new treat…

This study tracks the long-term safety of experimental cancer treatments in patients who previously participated in earlier Janssen trials. It follows 80 people with various cancers to monitor for serious side effects over time. The goal is to better understand the safety profile…